Empiric Azithromycin in COVID-19 Impacts the Respiratory Microbiome and Antimicrobial Resistome without Anti-inflammatory Benefit.

Langelier C, Glascock A, Maguire C, Van Phan H, Lydon E, Calfee C, Corry D, Kheradmand F, Baden L, Sekaly RP, McComsey G, Haddad E, Cairns C, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf J, Higuita N, Messer W, Davis M, Nadeau KC, Kraft M, Bime C, Schaenman J, Erle D, Atkinson M, Ehrlich LIR, Melamed E, Montgomery R, Shaw A, Hough C, Geng L, Hoch A, Hafler D, Augustine A, Becker P, Peters B, Ozonoff A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman M, Wilson M, Guan L, Maecker H, Steen H, Diray-Arce J, Rouphael N, Kleinstein S, Reed E, Levy O, Chu V